(Q34864208)

English

Paromomycin

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

Paromomycin. (English)

1 reference

Europe PubMed Central

5 August 2017

1 reference

ChEBI release 2020-05-28

Koert Ritmeijer

3

object named as

Koert Ritmeijer

1 reference

Europe PubMed Central

5 August 2017

author name string

Robert N Davidson

1

1 reference

Europe PubMed Central

5 August 2017

Margriet den Boer

2

1 reference

Europe PubMed Central

5 August 2017

publication date

23 October 2008

1 reference

Europe PubMed Central

5 August 2017

Transactions of the Royal Society of Tropical Medicine and Hygiene

1 reference

Europe PubMed Central

5 August 2017

103

1 reference

Europe PubMed Central

5 August 2017

653-660

1 reference

Europe PubMed Central

5 August 2017

7

1 reference

Europe PubMed Central

5 August 2017

The sensitivity of Leishmania species to aminosidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

TDR collaboration with the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Injectable paromomycin for Visceral leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

21 January 2018

The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Development and characterization of paromomycin-resistant Leishmania donovani promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methylbenzethonium chloride.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin).

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2008.09.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.TRSTMH.2008.09.008

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34864208&oldid=1957683530"